Krystal Biotech Reports Positive Interim Results for KB407 in Cystic Fibrosis Trial
I'm PortAI, I can summarize articles.
Krystal Biotech Inc. reported positive interim results from its Phase 1 CORAL-1 study of KB407 for cystic fibrosis, showing successful delivery of CFTR protein in airway cells. Transduction rates ranged from 29.4% to 42.1%. The treatment was well tolerated, with mostly mild adverse events. The company has submitted a design for a follow-up study, CORAL-3, to the FDA, with enrollment expected in the first half of 2026. Further details will be shared at study initiation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments